Please login to the form below

Not currently logged in
Email:
Password:

IQWiG

This page shows the latest IQWiG news and features for those working in and with pharma, biotech and healthcare.

Resurgent Diurnal raises £5.4m for twin product filings

Resurgent Diurnal raises £5.4m for twin product filings

IQWiG) concluded it had not been proven to be superior to generic hydrocortisone.

Latest news

More from news
Approximately 23 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • The gold standard of scientific evidence The gold standard of scientific evidence

    PBAC appraisals, 64% of NICE appraisals and all IQWiG appraisals relied on RCT-based evidence.

  • Digital disruption Digital disruption

    best patient outcomes - information that would probably come in very handy for submissions to the likes of NICE or IQWiG.

  • Stepping up to payer-driven market access Stepping up to payer-driven market access

    Combined with the demanding - and often less familiar - requirements of the GBA and IQWIG in Germany and other agencies in Europe, these changes make early understanding of the payer environment critical

  • The price is right? The price is right?

    IQWiG evaluations often focus on different patient populations from those used in the clinical trials. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely complex process.”.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    After regulatory clarity, the focus will certainly move to health technology assessment bodies, such as Germany's IQWiG and the UK's NICE, if biosimilars' place in clinical practice is to ... For its part IQWiG has yet to assess any biosimilar products.

More from intelligence
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Usually the G-BA also seeks the advice of expert Health Technology Assessment (HTA) body IQWiG (the Institute for Quality and Efficiency in Healthcare), to determine the level of added benefit ... The G-BA and IQWiG restricted these options to therapies

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics